Abstract:As COVID-19 ravages healthcare systems worldwide, cases of infection among patients with systemic lupus erythematosus (SLE) are increasingly reported. While there had been 2 reports on incident hospitalized cases from the US and France,1, 2 there have been no reports of SLE patients with COVID-19 infection from the Asia Pacific region. The Asia Pacific Lupus Collaboration (APLC) patient cohort comprises 3375 patients from 25 centers in Australia, China, Hong Kong, Indonesia Japan, Korea, Malaysia, New Zealand, Philippines, Singapore, Sri Lanka, Taiwan, Thailand.3 On 3 June, principal investigators of APLC centers were asked to respond to a brief email questionnaire regarding current or historical COVID-19 cases in their cohorts. Patients and the public were not involved in the conduct of this research. Table 1 describes the number of COVID-19 patients, number of SLE patients and the prevalence of hydroxychloroquine use. In total, only 3 cases of COVID-19 were reported. Here, we briefly describe their clinical course. Patient 1 was a 58-year-old Japanese woman with stable SLE, maintained on prednisolone monotherapy (5 mg daily) without hydroxychloroquine. Her daughter was diagnosed with COVID-19 infection and the patient was found to be positive for SARS-CoV-2 on screening. Although she was asymptomatic, her clinical course was complicated by severe thrombocytopenia (nadir 5 × 109/L) which required intravenous immunoglobulin and prednisolone 20 mg daily. The thrombocytopenia was attributed to SLE flare as its severity was assessed to be out of proportion to her asymptomatic COVID-19 infection. In addition, hypocomplementemia was observed. Platelet count eventually improved and she was discharged. Patient 2 was a 32-year-old Filipino woman with active lupus nephritis who was treated with hydroxychloroquine, mycophenolate mofetil and prednisolone 30 mg daily. She resided 5 hours away from her lupus center and had a history of poor treatment adherence. During the pandemic, only phone consultations were performed, during one of which she informed her rheumatologist that she had been initiated on hemodialysis at a local hospital for deteriorating renal function. Subsequently, her rheumatologist was informed that she had passed away from COVID-19 pneumonia at the provincial hospital. Details surrounding her COVID-19 infection were not accessible. Patient 3 was a 29-year-old Filipino woman with SLE (on hydroxychloroquine, azathioprine and low-dose prednisolone), hypertensive heart disease and chronic kidney disease who presented with bilateral COVID-19 pneumonia and peripheral edema. Concurrently, she was found to have active lupus nephritis which required increase in prednisolone to 50 mg daily. She was discharged when pneumonia and lupus nephritis improved. In summary, we report three cases of COVID-19 infection in SLE patients from the Asia Pacific, of which one was fatal. Notably, all three patients had active SLE which required escalation of treatment just before, or during treatment for COVID-19 infection, in contrast to reports from France.2 Importantly, patient 2 could not directly access her rheumatologist during the pandemic and only phone consultations were used. Further research on the impact of reduced care access and the utility of alternative care models, such as teleconsultation, is needed for patients with SLE. While the incidence of COVID-19 in SLE is unknown, 16 (4%) of the 450 patients in the Colombia Lupus Cohort developed symptomatic COVID-19 infection.1 Based on a report censored on 15 April in Hong Kong, none of the 1016 COVID-19 cases had a history of SLE.4 In this report, we describe only 3 cases identified among our 3375 SLE patients. Although we did not systematically capture infection rates in a protocolized manner, the low number of COVID-19 infections, at ~ 0.1% of the APLC cohort, does not suggest a major burden of COVID-19 among SLE patients. Possible reasons accounting for this included the low background prevalence of COVID-19 in the region compared with other parts of the world at the time of the report and increased measures taken by SLE patients to avoid infections. We eagerly await data from other SLE cohorts. The authors declare no competing interests. AL, RKR, EM and CJC contributed to the conception or design of the work. All authors contributed to the acquisition, analysis and interpretation of data. CJC, RKR and AL drafted the work. All coauthors revised it critically for important intellectual content. Final approval of the version published was obtained from all authors. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Principal Investigators of individual centers obtained valid written informed consent in accordance with local authority regarding ethical conduct of human research, which conformed to the provisions of the Declaration of Helsinki. In addition, Monash University ethics approval has been obtained to store the pooled database, perform analyses and subsequently publish the findings.

[The impact of COVID-19 in a cohort of patients with systemic sclerosis]

Clinical characteristics and disease course before and after SARS-CoV-2 infection in a large cohort of systemic sclerosis patients

COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients

Systemic Sclerosis (SSc) After COVID-19: A Case Report

Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases

Impact of the COVID-19 Pandemic on Health Care Access and Diagnosis of Pulmonary Arterial Hypertension Among Patients With Systemic Sclerosis

Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

Lung involvement in systemic sclerosis

Systemic sclerosis following COVID-19 infection with recurrent corticosteroid-induced scleroderma renal crisis

Effect of Traditional Therapeutics on Prevalence and Clinical Outcomes of Coronavirus Disease 2019 in Chinese Patients with Autoimmune Diseases

Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: Observations from an Indian inception cohort

Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors

COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series

Assessing the impact of long-term inhaled corticosteroid therapy on patients with COVID-19 and coexisting chronic lung disease: A multicenter retrospective cohort study

Impact of the COVID-19 pandemic on psychosocial health in rheumatic patients: A longitudinal study

Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Humoral and cellular response in convalescent COVID-19 lupus patients

Impact of COVID-19 on quality of life in survivors with pulmonary sequelae

COVID‐19 Infection in Patients with Systemic Lupus Erythematosus: Data from the Asia Pacific Lupus Collaboration

Impact of SARS-CoV-2 infection and COVID-19 pandemic on the morbidity and mortality of amyotrophic lateral sclerosis patients in Valencia, Spain